Gain Therapeutics Proxy Statement Filed
Ticker: GANX · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, annual-meeting
TL;DR
Gain Therapeutics DEF 14A filed, shareholders vote soon on exec pay & more.
AI Summary
Gain Therapeutics, Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting on June 24, 2025. The filing details executive compensation, including stock options granted to Matthias Alder on March 21, 2024, and Gene Mack on April 5, 2024. The company is in the pharmaceutical preparations industry and is incorporated in Delaware.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation and upcoming voting matters, allowing them to make informed decisions at the annual meeting.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the specific details within can reveal changes in executive compensation or corporate governance that may impact investor confidence.
Key Numbers
- 20250624 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20250429 — Filing Date (Date the proxy statement was officially submitted to the SEC.)
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Registrant
- Matthias Alder (person) — Executive
- Gene Mack (person) — Executive
- 20250429 (date) — Filing Date
- 20250624 (date) — Meeting Date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information for the upcoming annual meeting, including details on executive compensation and proposals to be voted upon.
When is the annual meeting of Gain Therapeutics, Inc. scheduled?
The annual meeting is scheduled for June 24, 2025.
Who are some of the individuals mentioned in relation to stock options?
Matthias Alder and Gene Mack are mentioned in relation to stock options granted in March and April 2024, respectively.
What is the industry of Gain Therapeutics, Inc. according to the filing?
Gain Therapeutics, Inc. is classified under the Pharmaceutical Preparations industry (SIC code 2834).
Where is Gain Therapeutics, Inc. incorporated?
Gain Therapeutics, Inc. is incorporated in Delaware (DE).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 by Matthias Alder regarding Gain Therapeutics, Inc. (GANX).